INTRODUCTION: HER-2 is a proto-oncogene of the tyrosine kinase receptor family on chromosome 17. Overexpression of this gene affects the growth and prognosis of some tumors. This study was performed to evaluate the expression of the HER-2 gene in patients with prostate cancer and its relation with the Gleason score. MATERIALS AND METHODS: Pathology specimens of all men with prostate cancer who had undergone radical prostatectomy without any supportive treatment were studied. The Gleason scores of the specimens and the expression of HER-2 gene were examined. The expression of HER-2 was scored between zero and 3+ in accordance with the HercepTest method. Patients with scores of 2+ and 3+ were considered to be positive for HER-2 overexpression. RESULTS: Of 150 cancerous prostate specimens evaluated, 20 (13.3%) were positive for HER-2 gene overexpression. A weakly positive HER-2 overexpression (2+) was seen in 15 of them (75%) and the remaining 5 (25%) were strongly positive. The Gleason score was not different between the HER-2-positive and HER-2-negative patients (P = .08). Fourteen out of 97 patients (14.4%) with a Gleason score less than 7 and 6 out of 53 (11.3%) with scores of 7 or greater were positive for HER-2 overexpression. CONCLUSION: The frequency of HER-2 gene overexpression is not very high in our patients with prostate cancer, and we failed to show any association of HER-2 expression and the Gleason score.
INTRODUCTION:HER-2 is a proto-oncogene of the tyrosine kinase receptor family on chromosome 17. Overexpression of this gene affects the growth and prognosis of some tumors. This study was performed to evaluate the expression of the HER-2 gene in patients with prostate cancer and its relation with the Gleason score. MATERIALS AND METHODS: Pathology specimens of all men with prostate cancer who had undergone radical prostatectomy without any supportive treatment were studied. The Gleason scores of the specimens and the expression of HER-2 gene were examined. The expression of HER-2 was scored between zero and 3+ in accordance with the HercepTest method. Patients with scores of 2+ and 3+ were considered to be positive for HER-2 overexpression. RESULTS: Of 150 cancerous prostate specimens evaluated, 20 (13.3%) were positive for HER-2 gene overexpression. A weakly positive HER-2 overexpression (2+) was seen in 15 of them (75%) and the remaining 5 (25%) were strongly positive. The Gleason score was not different between the HER-2-positive and HER-2-negative patients (P = .08). Fourteen out of 97 patients (14.4%) with a Gleason score less than 7 and 6 out of 53 (11.3%) with scores of 7 or greater were positive for HER-2 overexpression. CONCLUSION: The frequency of HER-2 gene overexpression is not very high in our patients with prostate cancer, and we failed to show any association of HER-2 expression and the Gleason score.
Authors: Nicolas Kozakowski; Caroline Hartmann; Hans Christoph Klingler; Martin Susani; Peter R Mazal; Anke Scharrer; Andrea Haitel Journal: Target Oncol Date: 2013-11-17 Impact factor: 4.493
Authors: Khalid Abubaker; Rodney B Luwor; Ruth Escalona; Orla McNally; Michael A Quinn; Erik W Thompson; Jock K Findlay; Nuzhat Ahmed Journal: Front Oncol Date: 2014-04-09 Impact factor: 6.244
Authors: Khalid Abubaker; Rodney B Luwor; Hongjian Zhu; Orla McNally; Michael A Quinn; Christopher J Burns; Erik W Thompson; Jock K Findlay; Nuzhat Ahmed Journal: BMC Cancer Date: 2014-05-06 Impact factor: 4.430